Old Web
English
Sign In
Acemap
>
authorDetail
>
Shirley Poon
Shirley Poon
Amgen
Prostate cancer
Medicine
Tolerability
Apalutamide
radionuclide therapy
2
Papers
1
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).
2020
Journal of Clinical Oncology
Ben Tran
Lisa G. Horvath
Matthew Rettig
Karim Fizazi
Martijn P. Lolkema
Tanya B. Dorff
Richard Greil
Jean-Pascal Machiels
Karen A. Autio
Sylvie Rottey
Nabil Adra
Rohan Garje
Felicia Roncolato
Scott T. Tagawa
Shahrokh F. Shariat
Mark Salvati
Shirley Poon
Hosein Kouros-Mehr
Show All
Source
Cite
Save
Citations (1)
340 Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer
2020
Journal for ImmunoTherapy of Cancer
Tanya B. Dorff
Matthew Rettig
Jean-Pascal Machiels
Martijn P. Lolkema
Karen Autio
Richard Greil
Sylvie Rottey
Nabil Adra
Mark Salvati
Shirley Poon
Daniel Tan
Gabor Jurida
Hosein Kouros-Mehr
Karim Fizazi
Ben Tran
Lisa G. Horvath
Show All
Source
Cite
Save
Citations (0)
1